Attention javascript est désactivé sur votre poste.
Ce site nécessite l'activation de javascript pour fonctionner correctement.
Follow our news on LinkedIn
Learn more
Follow our news on LinkedIn
Learn more
Our pipeline
OPM 101
OPM 102
OPM 201
COMETE
Partnering
Scientific news
Our innovation technologies
OncoSNIPER
Nanocyclix®
PROMETHE®
Investors
Message from the President
Investor Day 2023
Regulated informations [FR]
Press Releases
General Meetings [FR]
About us
Latest news
Our history
Management
Our HR policy
FederAidd
PROMETHE sector
CSR
Our approach
Our code of ethics and business conduct
Our carbon footprint
Contact us
Back to news
Financial
News
Press Release
Mon. 8 January
Letter to the shareholders
Share on
Time to change!
CONTENTS
Calls for Projects presented by OPM
The main sources of public financing
News and corporate life
Focus on OPM-101 market
Shareholder logbook
Read more
Read the others news
News
Press Release
Mon. 6 January
4th Letter to Shareholders
Read more
News
Press Release
Fri. 20 December
OPM reacquires rights to its OPM-201 program from Servier after a positive Phase I trial in healthy volunteers
Read more
News
Press Release
Tue. 22 October
OPM reports final results of its phase 1 study with RIPK2 inhibitor OPM-101
Read more
Read all news
Subscribe to the OPM newsletter
Subscribe to the newsletter to not miss any news!
Subscribe to the OPM newsletter